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Abstract: The use of erlotinib, an epidermal growth factor receptor
tyrosine kinase inhibitor, is considered safe in the treatment of
non-small cell lung cancer. Recently, cases of erlotinib-associated
interstitial lung disease have been reported. This disease entity
remains poorly understood and the histopathology is rarely docu-
mented. We describe two cases of histologically confirmed fatal
interstitial lung disease after erlotinib treatment for non-small cell
lung cancer. After starting erlotinib treatment both patients devel-
oped clinical and radiologic signs of interstitial lung disease result-
ing in respiratory failure and death. Autopsy confirmed diffuse
alveolar damage. As the use of erlotinib is increasing, physicians
should be aware of this potentially fatal complication. The sparse
data on the clinical presentation, radiographic patterns, and histo-
logic findings of epidermal growth factor receptor tyrosine kinase
inhibitor-associated interstitial lung disease are discussed.
(J Thorac Oncol. 2008;3: 1050–1053)
Erlotinib is an oral epidermal growth factor receptor tyrosinekinase inhibitor (EGFR TKI) approved for the treatment of
patients with advanced non-small cell lung cancer (NSCLC)
who have progressed after platinum based chemotherapy. It
improves quality of life and prolongs survival by 2 months
compared with placebo.1 It is generally considered safe, with
diarrhea and acneiform rash being the most common adverse
effects. However, recently cases of serious and fatal inter-
stitial lung disease (ILD) have been reported with the use
of EGFR TKIs.2
EGFR TKI-induced ILD remains a poorly understood
disease entity. The sparse data available comes mainly from case
reports, retrospective trial analyses and postmarketing safety
information, predominantly from Japanese patients treated with
gefitinib. Diagnosis of drug-induced ILD is often difficult and is
based on clinical, radiologic and, where available, pathologic
observations. However, as biopsy and autopsy studies have
rarely been obtained in cases of erlotinib-associated ILD the
histopathology is poorly documented. We report two cases of
histologically confirmed fatal erlotinib-induced ILD.
Case History 1
A 62-year-old female underwent a left upper lobectomy
for stage IIIA (T2N2M0) NSCLC in June 2006. Nine months
later she presented with an intracranial metastasis on the right
side of the pons for which neurosurgery and radiosurgery
were considered contraindicated. After obtaining informed
consent she was enrolled in a phase I clinical trial (approved
by the local medical ethics committee) evaluating whole
brain radiotherapy with concurrent and maintenance erlotinib
(150 mg/d). The whole brain radiotherapy, delivered in 10
fractions of 3 Gy, was well tolerated without neurologic
toxicity. She experienced one episode of self-limiting, grade
1 diarrhea and a self-limiting, grade 1 acneiform rash in the
first month of erlotinib treatment. On day 43 of erlotinib treat-
ment she developed progressive shortness of breath without a
cough or fever. No risk factors for aspiration such as decreased
consciousness or dysphagia, were present. A chest computed
tomography (CT) scan showed a new ground-glass attenuation
pattern located peripherally in the right upper zone. She was
treated empirically with oral amoxicillin (500 mg t.i.d.), bron-
chodilator inhalers, and oral dexamethasone (6 mg b.i.d.). How-
ever, her symptoms worsened and she was hospitalized on day
49 with peripheral cyanosis and severe hypoxia (peripheral
oxygen saturation 65% on room air). Arterial blood gas on 15
liter/min oxygen revealed a pH of 7.54, PaCO2 of 30 mm Hg,
PaO2 of 46 mmHg, HCO3 of 25 mmol/liter and base excess of
3.5 mmol/liter. Laboratory tests showed raised inflammatory
markers (leukocyte count 19.0  109; C-reactive protein level
83 mg/liter). Chest radiographs showed extensive consolidation
of the right lung. CT pulmonary angiography (CT-PA) showed
a widespread ground-glass attenuation pattern and alveolar con-
solidation without signs of pulmonary emboli or tumor (Figure
1A). A clinical diagnosis of ILD was made. Despite discontinu-
ing erlotinib on day 52 and treatment with supplemental oxygen,
nebulisers, intravenous dexamethasone (12 mg/d), and intrave-
nous antibiotics (amoxicillin [1000 mg q.i.d.] followed by eryth-
romcyin [1000 mg q.i.d.] and amoxicillin/clavulinic acid [1100
mg q.i.d.]) her condition deteriorated and she died 54 days after
commencing erlotinib. Autopsy of the lungs revealed hyaline
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membrane formation, type 2 pneumocyte hyperplasia, some
lymphocytic interstitial infiltrate, and multiple thrombi in the
small pulmonary arteries consistent with diffuse alveolar dam-
age (DAD) (Figure 1B). There was a single microscopic focus of
necrotic tumor tissue in the left lung and no evidence of pneu-
monia. The cause of death was reported as cardiopulmonary failure
secondary to DAD with erlotinib considered the causative agent.
Case History 2
A 62-year-old nonsmoker was diagnosed with stage
IIIB (T2N3M0) NSCLC in August 2007. Because of her
preexisting scleroderma, with associated bilateral lung fibro-
sis, traction bronchiectasis, and restrictive pulmonary func-
tion impairment, chemotherapy was deemed inappropriate.
As female gender and a nonsmoking history predict a good
response to EGFR TKI therapy she was started on erlotinib
(150 mg/d). After 4 weeks of erlotinib treatment she devel-
oped a transient, grade 1 acneiform rash. On day 30 she was
hospitalized with a 3-day history of worsening shortness of
breath, fever, and dry cough. On examination she was in respi-
ratory distress with bilateral fine inspiratory crepitations on
auscultation. Arterial blood gas on 3 liter/min oxygen revealed a
pH of 7.53, PaCO2 of 28 mm Hg, PaO2 of 68 mm Hg, HCO3 of
22.4 mmol/liter, and base excess of 1.0 mmol/liter. Laboratory
tests showed raised inflammatory markers (leukocyte count
11.4  109; C-reactive protein level 57 mg/liter). Serial chest
radiographs showed progressive consolidation of the lower
zones. A high resolution CT scan showed new extensive bilat-
eral ground glass attenuation and bilateral pleural effusions (in
addition to the preexisting pulmonary fibrosis, lung tumor, and
mediastinal and hilar lymphadenopathy) (Figure 2A). A clinical
diagnosis of erlotinib-induced ILD was made. Despite discon-
tinuing erlotinib on day 31, supplemental oxygen and treatment
with oral prednisolone (60 mg/d), intravenous antibiotics
(amoxicillin/clavulinic acid [1100 mg q.i.d.], followed by ceftri-
axon [2000 mg/d] and gentamycin [350 mg/d]) her condition
deteriorated. She died 34 days after commencing erlotinib.
Autopsy of the lungs revealed extensive necrosis in the primary
lung tumor with mediastinal lymph node metastases and bilat-
eral pulmonary fibrosis. In addition, a pattern of bilateral DAD
was seen with alveolar fluid, fibroblast proliferation, fibrin dep-
osition, hyaline membrane formation, and type 2 pneumocyte
hyperplasia (Figure 2B). The cause of death was reported as
respiratory failure secondary to DAD and (preexisting) intersti-
tial fibrosis.
DISCUSSION
In the absence of other etiologies, and the temporal
relationship between the use of erlotinib and the onset of
symptoms, the fatal ILD in these 2 patients were considered
erlotinib-related. The overall incidence of ILD in patients
treated with erlotinib and gefitinib is estimated by the FDA to
be 0.8% and 1%, respectively.3,4 An independent analysis of
the TRIBUTE trial identified fatal erlotinib-induced ILD in
only 3 of 526 (0.6%) patients receiving erlotinib.5 The low
incidence of ILD explains why, despite a number of large
prospective trials, it is only a recently recognized complica-
tion of EGFR TKI therapy and remains poorly understood.
As demonstrated above, patients commonly present with
acute onset of progressive dyspnoea, with or without cough
or low-grade fever, often require hospitalization. The median
time of onset after commencing erlotinib treatment is 47 days
but ranges from 5 days to more than 9 months.3
Risk factors for erlotinib-induced ILD remain unknown.
More is known about gefitinib-induced ILD of which the re-
ported incidence is consistently higher in Japan (1.6–3.5%) as
FIGURE 1. A, Case 1:CT pulmonary angiography (CT-PA)
showing a bilateral ground-glass attenuation pattern with
alveolar consolidation. B, Case 1: Hematoxylin and eosin
staining of the lung tissue at autopsy showing exudative
phase of diffuse alveolar damage (DAD) with hyaline mem-
branes lining the alveolar spaces (black arrows) and lympho-
cytic interstitial infiltrate (blue arrows).
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compared with other parts of the world (0.3%).2 The reason for
this geographic difference is unclear. A retrospective analysis of
112 patients with NSCLC treated with gefitinib found preexist-
ing pulmonary fibrosis to be an important risk factor for devel-
oping fatal ILD.6 The preexisting pulmonary fibrosis in case 2
may have contributed to her developing erlotinib-induced ILD.
However, not all patients with pulmonary fibrosis develop pro-
gressive ILD with EGFR TKIs.7 Another retrospective analysis
of 1976 Japanese patients with NSCLC treated with gefitinib
showed a positive smoking history, male gender, and coinci-
dence of interstitial pneumonia to be significantly associated
with gefitinib-induced ILD.8 The 20 pack-year smoking history
in case 1 may have increased her risk of developing erlotinib-
induced ILD. More studies are needed to confirm these findings
and to determine if these clinical characteristics can guide
patient selection/exclusion for erlotinib therapy.
Radiologic changes of EGFR TKI-related ILD are non-
specific and seem to be similar to those of other drug-associated
lung injury. A retrospective study of the West Japan Thoracic
Oncology Group describes 2 main patterns of gefitinib-induced
ILD: (1) nonspecific ground-glass attenuation and (2) extensive
bilateral ground-glass attenuation or airspace consolidations
with traction bronchiectiasis.9 The latter was seen in our 2
patients.
The limited histopathological data from cases of EGFR
TKI-associated ILD indicates that the commonest pathologic
diagnosis is one of DAD, as was seen in our cases.5 DAD is
a nonspecific reaction and the characteristic features depend
on the timing of the biopsy. During the exudative phase, there
is interstitial edema, hyaline membrane formation, variable
amounts of acute and chronic inflammation, and type II cell
hyperplasia. Although microvascular thromboemboli, as seen
in case 1, are frequently found in DAD, these have been
reported in only one other erlotinib treated patient.10
Management of EGFR TKI-induced ILD consists of dis-
continuing EGFR TKI treatment, supportive therapy (including
supplemental oxygen and mechanical ventilation when neces-
sary) and high dose steroids. Although resolution has been
reported, many patients die of progressive respiratory failure.
Data on mortality rates is limited to gefitinib-associated ILD and
is estimated at 33 to 44%.4
In conclusion, erlotinib is considered generally safe and
well tolerated. However, physicians should be aware of ILD
as a potential (fatal) complication. At increased risk are patients
with preexisting interstitial pulmonary fibrosis or interstitial
pneumonia, in whom EGFR TKI treatment is relatively contra-
indicated. Any acute onset of respiratory symptoms or radiologic
changes in patients treated with erlotinib warrant evaluation. If
investigations reveal no other explanation for the clinical and
radiologic presentation erlotinib should be discontinued and the
patient treated appropriately. Further research is needed to iden-
tify the risk factors and pathophysiology. This will guide patient
selection/exclusion for erlotinib therapy and help develop more
effective treatment strategies.
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